First 90 Days: Page
-
Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
Getty Images
First 90 DaysFirst 90 Days: Adaptive Biotech’s Tycho Peterson
A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.
By Michael Gibney • Sept. 1, 2022 -
Permission granted by Brian Goff.
Q&A // First 90 DaysFirst 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
By Alexandra Pecci • Aug. 22, 2022 -
Getty Images
Q&A // First 90 DaysAnjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
By Kim Ribbink • July 15, 2022 -
Permission granted by Editas/Gilmore O'Neill
Q&A // First 90 DaysFirst 90 Days: Editas Medicine’s Gilmore O’Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
By Michael Gibney • June 13, 2022 -
Permission granted by David Jimenez.
Q&A // First 90 DaysFirst 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
Permission granted by Sosei Heptares/Chris Cargill
Q&A // First 90 DaysFirst 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
Permission granted by Michelle Keefe.
Q&A // First 90 DaysFirst 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
By Taren Grom • May 23, 2022 -
Real Chemistry/PharmaVoice
Q&ALessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership
Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.
By Taren Grom • April 4, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
Q&ABioMarin’s new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
By Taren Grom • March 21, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022
Previous
To find more content, use the "Topics" in the menu above.
